ANI Pharmaceuticals (ANIP) legal chief sells 500 shares under 10b5-1 plan

Rhea-AI Filing Summary

ANI Pharmaceuticals Inc. senior vice president, general counsel and secretary Meredith Cook reported an open-market sale of 500 shares of common stock at $78.16 per share. The transaction occurred on May 13, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025.

After this sale, Cook directly holds 78,390 shares of ANI Pharmaceuticals common stock, indicating she retains a substantial equity position in the company despite the relatively small disposition.

Insider Trade Summary 10b5-1

Net Seller: 500 shares ($39,080)

Net Sell 1 txn

Insider Cook Meredith

Role SR. VP, GENERAL COUNSEL & SEC.

Sold 500 shs ($39K)

Type	Security	Shares	Price	Value
Sale	Common Stock	500	$78.16	$39K

Holdings After Transaction: Common Stock — 78,390 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 500 shares Sale price: $78.16 per share Shares owned after transaction: 78,390 shares +2 more

5 metrics

Shares sold 500 shares Open-market sale of common stock on May 13, 2026

Sale price $78.16 per share Price for the 500 shares sold

Shares owned after transaction 78,390 shares Direct holdings following the sale

Transaction type Open-market sale (Code S) Non-derivative common stock transaction

Trading plan adoption date September 15, 2025 Rule 10b5-1 plan governing this sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Meredith

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP, GENERAL COUNSEL & SEC.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/13/2026		S(1)		500	D	$78.16	78,390	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

Remarks:

	/s/ Meredith W. Cook	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Meredith Cook?

ANI Pharmaceuticals reported that executive Meredith Cook sold 500 shares of common stock in an open-market transaction. The sale was executed at $78.16 per share and left her with 78,390 shares directly owned after the transaction.

At what price did Meredith Cook sell ANI Pharmaceuticals (ANIP) shares?

Meredith Cook sold 500 ANI Pharmaceuticals shares at $78.16 per share. This open-market transaction reflects the price per share disclosed for the sale and does not, by itself, indicate broader company performance or valuation trends.

How many ANI Pharmaceuticals (ANIP) shares does Meredith Cook hold after the sale?

Following the reported transaction, Meredith Cook directly owns 78,390 shares of ANI Pharmaceuticals common stock. This post-transaction holding shows she retains a significant equity stake even after selling a relatively small number of shares in the open market.

Was Meredith Cook’s ANI Pharmaceuticals (ANIP) sale under a Rule 10b5-1 plan?

Yes. The filing states that Meredith Cook’s sale was effected pursuant to a Rule 10b5-1 trading plan. That plan was adopted on September 15, 2025, indicating the transaction was pre-scheduled rather than timed opportunistically based on short-term market movements.

What role does Meredith Cook hold at ANI Pharmaceuticals (ANIP)?

Meredith Cook serves as senior vice president, general counsel and secretary at ANI Pharmaceuticals. Her position makes her a reporting officer for insider transactions, which is why this open-market sale of 500 shares was disclosed on a Form 4 filing.

How many ANI Pharmaceuticals (ANIP) shares did Meredith Cook sell in this Form 4?

The Form 4 shows that Meredith Cook sold 500 shares of ANI Pharmaceuticals common stock. This was the only transaction reported in the filing and was categorized as an open-market sale of non-derivative common stock held directly.